NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 18:58இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Zota Health Q2 FY27 Concall: Revenue Up 54.6% to ₹199.33 Cr; EBITDA Turns Positive
Zota Health Care released its Q2 FY27 earnings call transcript, highlighting a 54.6% YoY jump in consolidated revenue to ₹199.33 crore, driven by 76.3% sales growth in its Davaindia retail chain to ₹168.47 crore. Consolidated EBITDA turned positive at ₹7.92 crore (3.97% margin) versus negative ₹9.55 crore in Q1 FY27, while net loss narrowed sequentially to ₹25.96 crore from ₹43.94 crore. Store expansion was consciously moderated during the quarter to 20 additions (net 15 stores), bringing total network count to 2,840 stores. Additionally, the company converted ₹119.52 crore of unsecured loans and interest due from its Davaindia subsidiary into equity.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the full transcript of the Q2 FY27 earnings conference call held on October 29, 2026.
ஏன் இது முக்கியம்Provides granular operational insights, showing sequential turnaround in EBITDA as management temporarily paused aggressive store expansion to consolidate store-level economics.
Consolidated Revenue Q2 FY27: ₹199.33 கோடிDavaindia Sales Q2 FY27: ₹168.47 கோடிConsolidated EBITDA: ₹7.92 கோடிConsolidated Net Loss: ₹25.96 கோடிTotal Stores as of Sep 30, 2026: 2,840Loan converted to equity: ₹119.52 கோடி
📅 குறுகிய காலம்Informational; the transcript details operational metrics such as higher GMV per store and improved EBITDA, confirming the financial trend already reported in results.
📈 நீண்ட காலம்Long-term trajectory depends on retail store maturation (COCO stores reaching target throughput) and achieving sustainable net profitability across the 2,800+ store footprint.
⚠ அபாய எச்சரிக்கைகள்
Continued bottom-line net losses (₹25.96 crore in Q2 FY27)
Capital-intensive retail expansion with plans to re-accelerate store additions in H2 FY27
👀 கவனிக்க வேண்டியவை
Track whether EBITDA margins sustain above zero as store expansion re-accelerates in H2 FY27, and monitor progress toward reducing the consolidated net loss.
Q2 FY27 Investor Presentation: Revenue reaches ₹199.3 Cr, net loss narrows to ₹26.0 Cr
Zota Health Care released its Q2 FY27 investor presentation, reporting consolidated revenue from operations of ₹199.33 Cr (up 54.6% YoY compared to ₹128.95 Cr in Q2 FY26). Operating profit turned positive to ₹3.06 Cr from an operating loss of ₹11.60 Cr in Q1 FY27, though net losses continued at ₹25.96 Cr due to high depreciation and lease finance costs. The Davaindia retail chain reached 2,840 active stores (1,859 COCO and 981 FOFO), contributing ₹168.47 Cr or 84.5% of total Q2 revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota published its detailed Q2 FY27 operational and financial deck highlighting store footprint additions and sequential reduction in operating and net losses.
ஏன் இது முக்கியம்Davaindia is scaling rapidly and now accounts for the vast majority of revenues, but continued net losses and rising lease/employee expenses weigh on overall profitability.
Q2 FY27 Revenue from Operations: ₹199.33 கோடிQ2 FY27 Net Loss: ₹25.96 கோடிDavaindia Store Count: 2,840 storesQ2 FY27 Gross Margin: 60.17%
📅 குறுகிய காலம்Sequential narrowing of operating and net losses provides relief, but cash burn across new store openings remains in focus.
📈 நீண்ட காலம்The company's pivot to a generic retail chain via Davaindia provides massive top-line growth, but structural value creation depends on achieving net profitability and store maturity.
⚠ அபாய எச்சரிக்கைகள்
Persistent consolidated net losses (₹25.96 Cr in Q2 FY27, TTM net profit negative).
High operating leverage and store expansion overheads (depreciation of ₹28.66 Cr and employee costs of ₹70.17 Cr in Q2).
👀 கவனிக்க வேண்டியவை
Track whether store-level unit economics improve to turn Davaindia operating margins sustainable, and monitor high depreciation and finance costs impacting the bottom line.
Zota Q2FY27 Revenue Rises 54.6% YoY to ₹199.3 Cr; EBITDA Turns Positive at ₹7.92 Cr
Zota Health Care reported a 54.58% YoY increase in consolidated revenue from operations to ₹199.33 crore for Q2FY27, driven by a 76.25% surge in Davaindia retail sales to ₹168.47 crore. EBITDA turned positive sequentially to ₹7.92 crore (3.97% margin) from an operating loss of ₹9.55 crore in Q1FY27. Net store expansion was moderated during the quarter to 15 stores (20 additions, 5 closures), taking the total Davaindia network to 2,840 stores. Additionally, Zota converted ₹119.52 crore of unsecured debt and interest from subsidiary Davaindia Health Mart into equity.
உச்சம் நம்பிக்கை
என்ன மாறியதுOperating profitability swung back into positive territory sequentially following a quarter of deliberate moderation in retail store rollouts.
ஏன் இது முக்கியம்Demonstrates operating leverage and cash-flow discipline in the retail Davaindia network following heavy TTM net losses of ₹104 crore.
Revenue from Operations (Q2FY27): ₹19,933.14 லட்சம்EBITDA (Q2FY27): ₹791.72 லட்சம்Davaindia Sales: ₹16,846.81 லட்சம்Total Davaindia Stores: 2,840Converted Subsidiary Debt: ₹119.52 கோடி
📅 குறுகிய காலம்Positive sequential earnings turnaround is likely to improve investor sentiment around unit economics of the aggressive retail footprint.
📈 நீண்ட காலம்Success hinges on sustaining store-level productivity and positive net earnings as network additions scale back up toward annual targets.
⚠ அபாய எச்சரிக்கைகள்
Working capital drag from aggressive expansion across a 2,800+ store network
Export sales declined YoY from ₹1,094.98 lakhs to ₹470.09 lakhs
👀 கவனிக்க வேண்டியவை
Track whether EBITDA margins sustain above 4% in upcoming quarters as management plans to re-accelerate store openings in H2FY27.
Zota Health Care Standalone Q2 Net Profit Falls 89% YoY to ₹1.12 Cr Despite 27% Revenue Rise
Zota Health Care reported standalone revenue from operations of ₹126.07 crore for Q2 FY27 (quarter ended September 30, 2026), up 26.8% YoY from ₹99.42 crore in Q2 FY26. Standalone net profit declined sharply by 88.7% YoY to ₹1.12 crore compared to ₹9.91 crore in the year-ago period, pressured by higher purchase costs and operating expenses. For H1 FY27, standalone revenue reached ₹253.09 crore against ₹177.43 crore in H1 FY26, while net profit dropped to ₹3.02 crore from ₹15.81 crore. In addition, the company converted an outstanding unsecured loan of ₹119.52 crore into equity shares of subsidiary Davaindia Health Mart Limited.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota reported standalone Q2 FY27 earnings showing significant margin contraction and capitalized ₹119.52 crore of intercompany debt into Davaindia Health Mart equity.
ஏன் இது முக்கியம்While top-line growth remains solid at over 26%, standalone margins have deteriorated severely, and store network expansion via Davaindia continues to require substantial balance sheet capital.
📅 குறுகிய காலம்Earnings miss and severe profit contraction on a standalone basis are likely to weigh negatively on market sentiment.
📈 நீண்ட காலம்The company is directing heavy financial support to Davaindia retail expansion; sustaining long-term value will depend on Davaindia achieving operational breakeven.
High capital commitment and intercompany loan exposure to subsidiary Davaindia Health Mart
👀 கவனிக்க வேண்டியவை
Track the full consolidated earnings detail to assess subsidiary Davaindia's retail burn rate and margin pressure across the retail pharmacy network.
Zota Health Care Infuses ₹19.91 Cr into Subsidiary Davaindia via Rights Issue
Zota Health Care has acquired 39,228 equity shares of its wholly owned subsidiary, Davaindia Health Mart Limited, through a rights issue for a total cash consideration of ₹19.91 crore. The shares were subscribed at ₹5,075 each (including a premium of ₹5,065 per share) on October 01, 2026. The investment aims to support the working capital needs of Davaindia, which operates the COCO generic pharmacy chain. Davaindia reported FY26 turnover of ₹267.71 crore and had 1,855 stores as of June 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota subscribed to 39,228 equity shares of its 100% subsidiary Davaindia Health Mart Limited for ₹19.91 crore, maintaining 100% ownership.
ஏன் இது முக்கியம்The infusion supports working capital for Davaindia's rapidly growing retail footprint, which is Zota's primary growth driver but also capital-intensive.
முதலீட்டுத் தொகை: ₹19.91 கோடிInvestment vs TTM revenue: ~3.5%Price per share: ₹5,075.00Subsidiary FY26 revenue: ₹267.71 கோடிSubsidiary store count: 1,855 stores (as on June 30, 2026)
📅 குறுகிய காலம்Neutral; this is an internal capital reallocation to fund working capital needs of an existing subsidiary without external dilution.
📈 நீண்ட காலம்Davaindia's rapid revenue scaling (from ₹44.8 Cr in FY24 to ₹267.7 Cr in FY26) is central to Zota's retail thesis, but sustained cash burn requires monitoring.
⚠ அபாய எச்சரிக்கைகள்
High working capital intensity in expanding retail store network
Consolidated profitability remains under pressure (TTM PAT of ₹-68 Cr)
👀 கவனிக்க வேண்டியவை
Track whether working capital support translates into improved store-level profitability and working capital turnover in upcoming Davaindia operating updates.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Zota Clarifies on IiAS 'Against' Call: Caps Promoter Pay at ₹12 Cr Till FY30
Zota Health Care has issued a response to proxy advisory firm IiAS, which recommended voting 'AGAINST' key AGM resolutions regarding promoter re-appointment, remuneration, and related party transactions (RPTs). The company clarified that cumulative promoter remuneration is capped at ₹12.00 crore per year until FY30, defending it against consolidated revenue growth of 83.86% in FY26. Zota also defended financial support to its 87.78% subsidiary, Everyday Herbal Beauty Care (EHBCL), noting that Davaindia derives around 27% of its revenue from OTC products largely manufactured by EHBCL. The AGM is scheduled for September 28, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota issued a formal rebuttal to proxy advisory firm IiAS's recommendation to vote against promoter re-appointment, remuneration limits, and subsidiary related party transactions.
ஏன் இது முக்கியம்Proxy advisor pushback highlights potential governance concerns regarding high promoter representation and RPTs, though management has capped cumulative promoter pay at ₹12 crore per year.
Annual promoter remuneration upper cap: ரூ. 12.00 கோடிStake in subsidiary EHBCL: 87.78%Davaindia OTC revenue share: around 27%FY26 Consolidated revenue growth: 83.86% YoYRemuneration cap vs TTM revenue: ~2.1%
📅 குறுகிய காலம்Shareholder scrutiny may increase heading into the September 28, 2026 AGM, though promoter holding stands at 49.38%.
📈 நீண்ட காலம்Institutional confidence will depend on how effectively the company resolves governance perceptions, controls RPTs, and returns to net profitability after TTM losses of ₹68 crore.
⚠ அபாய எச்சரிக்கைகள்
Governance dispute over excessive promoter board representation and office of profit positions
Material related-party transactions and financial assistance provided to 87.78% subsidiary EHBCL
👀 கவனிக்க வேண்டியவை
Watch the AGM voting results on September 28, 2026, to assess whether institutional and retail public shareholders support management's resolutions or align with the proxy advisor.
ZOTA Q1 FY27 Call: Revenue Up 67.6% YoY to ₹173.6 Cr, Store Network Reaches 2,825
Zota Health Care released its Q1 FY27 earnings call transcript highlighting a 67.6% YoY jump in operational revenue to ₹173.60 Cr and a gross margin of 61.96%. The company expanded its Davaindia store network to 2,825 locations (1,855 COCO and 970 FOFO) following a net addition of 246 stores during the quarter. Quarterly customer footfalls surged to ~60 lakhs compared to ~35 lakhs in Q1 FY26, driving total GMV to ₹164.02 Cr. Management noted it will moderate store additions in Q2 FY27 to focus on store productivity before re-accelerating expansion in H2 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the formal transcript for the Q1 FY27 earnings conference call held on August 14, 2026.
ஏன் இது முக்கியம்Provides granularity on retail store ramp-up, unit economics, gross margins, and management's strategy to balance store additions with profitability.
Q1 FY27 Revenue: ₹173.60 கோடிGross Margin: 61.96%Total Davaindia Stores: 2,825Net Store Additions (Q1): 246Quarterly Footfall: 60 லட்சம்
📅 குறுகிய காலம்Informational filing; performance details were already reported. Expansion moderation in Q2 FY27 will be monitored for employee cost optimization.
📈 நீண்ட காலம்Sustained rapid network rollout and migration to generic retail support scale, though bottom-line turnaround depends on store maturation and cost absorption.
⚠ அபாய எச்சரிக்கைகள்
High upfront employee and operational overheads from aggressive COCO store additions
Working capital intensity and inventory management risks across 2,800+ retail stores
👀 கவனிக்க வேண்டியவை
Track store-level productivity and EBITDA margin improvement in upcoming quarters as new COCO stores mature, alongside working capital efficiency across the 2,800+ store footprint.
Zota Health Care Q1FY27: Revenue Grows to ₹173.6 Cr, Net Loss Widens to ₹43.9 Cr
Zota Health Care reported a 67% YoY increase in consolidated revenue to ₹173.60 Cr for Q1FY27, primarily driven by its Davaindia retail segment which now contributes 83% of total sales. However, the company's net loss widened significantly to ₹43.94 Cr from a loss of ₹13.78 Cr in Q1FY26, impacted by high employee costs of ₹61.12 Cr and depreciation of ₹27.75 Cr. The retail footprint reached 2,825 stores with 264 additions during the quarter. Management has indicated a strategic moderation in store expansion for Q2FY27 to focus on store-level productivity and execution.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from aggressive store expansion (adding 264 stores in Q1) to a period of 'moderated expansion' in Q2FY27 to assess store-level performance and productivity.
ஏன் இது முக்கியம்While top-line growth is robust, the widening losses and negative EBITDA (₹-9.55 Cr) indicate that the current rapid expansion of Company-Owned Company-Operated (COCO) stores is straining the bottom line.
Q1FY27 Revenue: ₹173.60 கோடிQ1FY27 Net Loss: ₹43.94 கோடிDavaindia Store Count: 2,825QIP Fundraise: ₹350 கோடிQ1 வருவாய் vs TTM வருவாய்: 36.2%Gross Margin (Consolidated): 61.96%
📅 குறுகிய காலம்The stock may face pressure due to the widening net loss and negative EBITDA, despite the strong revenue growth figures.
📈 நீண்ட காலம்The long-term success depends on the company's ability to leverage its massive 2,800+ store network to achieve economies of scale and move toward PAT-level profitability.
⚠ அபாய எச்சரிக்கைகள்
Widening net losses
High operational burn rate (Employee costs at 35% of revenue)
Execution risk in the COCO retail model
Negative EBITDA of ₹9.55 Cr in Q1FY27
👀 கவனிக்க வேண்டியவை
Investors should monitor the management's ability to turn store-level EBITDA positive as they moderate expansion in Q2FY27. Key metrics to watch include the reduction in employee costs as a percentage of revenue and the stabilization of the COCO store model.
67.6% Revenue Growth in Q1 FY27; 264 New Stores Added but EBITDA Swings to Loss
Zota Health Care reported a robust 67.6% YoY revenue growth to ₹173.60 Cr for Q1 FY27, primarily driven by the aggressive expansion of its Davaindia retail network. However, the company recorded an EBITDA loss of ₹9.55 Cr, a sharp decline from the ₹4.83 Cr profit in Q1 FY26, reflecting the high costs of rapid store rollouts and brand investments. The company added 264 stores during the quarter, bringing the total to 2,825, but management has signaled a 'moderation' in expansion for Q2 FY27 to focus on store-level productivity. Strategic moves include appointing Akshay Kumar as brand ambassador and acquiring an 80% stake in an IT consultancy to bolster digital infrastructure.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota has achieved significant scale in its retail footprint but has transitioned from a profitable quarter to an operating loss due to aggressive expansion costs.
ஏன் இது முக்கியம்The massive revenue growth validates the demand for affordable generics, but the EBITDA loss highlights the financial strain of the COCO (Company Owned Company Operated) model, which requires high upfront investment.
📅 குறுகிய காலம்The market may react cautiously to the EBITDA loss and the management's decision to slow down expansion in the immediate next quarter.
📈 நீண்ட காலம்The structural shift toward organized generic retail remains a major growth lever; long-term value depends on converting the 2,800+ store network into a profitable ecosystem.
⚠ அபாய எச்சரிக்கைகள்
Operating loss (EBITDA negative)
High working capital intensity of COCO stores
Execution risk in managing a rapidly expanding retail network
Potential slowdown in growth due to planned expansion moderation
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the 'moderation' phase in Q2 FY27 to see if the company can improve store-level EBITDA and reduce the burn rate from its Company-Owned (COCO) stores. The key metric to watch will be the stabilization of operating margins as the new stores mature.
ZOTA Q1 Standalone Revenue Up 62.8% YoY to ₹127 Cr; Net Profit Declines to ₹1.90 Cr
Zota Health Care reported a strong standalone revenue growth of 62.8% YoY, reaching ₹127.03 Cr for Q1 FY27. However, standalone net profit saw a sharp decline of 67.8% YoY to ₹1.90 Cr, down from ₹5.90 Cr in the year-ago period, primarily due to a surge in 'Other Expenses' to ₹43.30 Cr. The company continues its aggressive retail push, investing ₹20.20 Cr in its subsidiary Davaindia Health Mart during the quarter. While the top-line expansion is robust, the bottom line remains under significant pressure from high operational costs associated with store rollouts.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota has reported its Q1 FY27 results, showing a significant scale-up in revenue but a contraction in profitability margins compared to the previous year.
ஏன் இது முக்கியம்The results validate the company's ability to drive sales through its Davaindia retail chain, but highlight the financial strain of rapid expansion, with operational costs currently outpacing revenue growth.
Standalone Revenue (Q1 FY27): ₹127.03 கோடிStandalone PAT (Q1 FY27): ₹1.90 கோடிQ1 வருவாய் vs TTM வருவாய்: 26.5%Investment in Davaindia: ₹20.20 கோடிConsolidated Lease Liability: ₹233.47 கோடிOther Expenses (Q1 FY27): ₹43.30 கோடி
📅 குறுகிய காலம்The stock may face pressure due to the sharp decline in net profit despite the strong revenue growth, as the market digests the high cost of expansion.
📈 நீண்ட காலம்The long-term trajectory depends on the company's ability to turn its 1,000+ store network profitable. The current high-growth, low-margin phase is typical for retail expansion but increases execution risk.
⚠ அபாய எச்சரிக்கைகள்
High operational expense growth (167% YoY)
Significant lease liabilities relative to market cap
Margin contraction in the core standalone business
👀 கவனிக்க வேண்டியவை
Investors should monitor the 'Other Expenses' line item in coming quarters to see if the company can achieve operating leverage as new Davaindia stores mature. The high lease liability of ₹233 Cr warrants a close watch on finance costs and cash flow stability.
Rs 119.52 Cr Debt-to-Equity Conversion in Subsidiary Davaindia Health Mart
Zota Health Care has converted an unsecured loan of Rs 119.52 crore (including accumulated interest) into equity shares of its wholly-owned subsidiary, Davaindia Health Mart Limited. The acquisition of 2,35,512 shares was executed at Rs 5,075 per share, including a significant premium. This move strengthens the subsidiary's capital base and improves the group's consolidated net worth. Davaindia is the company's primary growth engine, with its turnover surging from Rs 44.77 crore in FY24 to Rs 267.71 crore in FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota Health Care converted its outstanding inter-company loans to its retail subsidiary into equity capital, formalizing its investment in the Davaindia brand.
ஏன் இது முக்கியம்This improves the subsidiary's balance sheet and the group's consolidated net worth while reducing internal debt. It signals a long-term commitment to the generic retail pharmacy model which now accounts for over 55% of group revenue.
Transaction Value: Rs 119.52 கோடிValue vs Group Net Worth: ~13.4%Subsidiary FY26 Turnover: Rs 267.71 கோடிConversion Price per Share: Rs 5,075Store Count (June 2026): 1,855
📅 குறுகிய காலம்The market may view this as a positive balance sheet cleanup, though it does not involve a fresh cash infusion.
📈 நீண்ட காலம்The rapid scaling of Davaindia (6x revenue growth in two years) is the core structural story; this restructuring supports that expansion by strengthening the subsidiary's equity base.
⚠ அபாய எச்சரிக்கைகள்
Parent company remains loss-making at the PAT level (TTM PAT -Rs 18 Cr)
High reliance on the retail franchise model for growth
👀 கவனிக்க வேண்டியவை
Investors should monitor if this capital restructuring leads to improved operational margins for the Davaindia retail chain, which is currently the main revenue driver for the loss-making parent company.
264 New Stores Opened in Q1FY27; Total Davaindia Network Reaches 2,825
Zota Health Care expanded its Davaindia retail network by opening 264 new stores in Q1FY27, bringing the total count to 2,825. The expansion was heavily weighted towards Company Owned Company Operated (COCO) stores, which saw 201 additions, while Franchisee Owned (FOFO) stores added 63 units. This quarterly growth represents a 10.2% increase in total footprint, aligning with the company's FY27 target of 500-800 new stores. Despite the rapid expansion, the company must address its TTM net loss of ₹18 Cr and low operating margins of 6.4%.
உச்சம் நம்பிக்கை
என்ன மாறியதுZota added 264 stores to its Davaindia retail chain in Q1FY27, significantly increasing its physical presence in the generic pharmacy market.
ஏன் இது முக்கியம்This expansion is the primary driver for Zota's goal to capture market share from unorganized pharmacies; however, the high proportion of COCO stores increases operational overhead and capital requirements.
New stores opened (Q1FY27): 264Total stores (30-06-2026): 2,825Store count growth (QoQ): 10.2%COCO store count: 1,855FOFO store count: 970
📅 குறுகிய காலம்The market is likely to react positively to the aggressive execution of the store rollout strategy, which is a key component of the company's growth narrative.
📈 நீண்ட காலம்Structural growth depends on the company's ability to achieve store-level profitability and reverse its current TTM net loss of ₹18 Cr as the network scales.
👀 கவனிக்க வேண்டியவை
Monitor the Q1FY27 earnings to see if the 10% store count growth translates into revenue growth and if the company can improve its operating margins from the current 6.4% level.
Zota Health Care Acquires 80% Stake in Globotask IT Consultancy for ₹25 Lakhs
Zota Health Care Limited has acquired an 80% controlling stake in Globotask IT Consultancy Services Private Limited (GITCPL) for a total cash consideration of ₹25 lakhs. GITCPL is an IT services firm specializing in software development, ERP solutions, and cloud-based applications, reporting a turnover of ₹19.28 lakhs in FY 2025-26. This acquisition is intended to internalize IT solutions and digital infrastructure management for Zota and its subsidiaries. Following this transaction, GITCPL has become a subsidiary of Zota Health Care.
முக்கிய அம்சங்கள்
Acquisition of 80% stake (8,000 equity shares) for a total cash consideration of ₹25,00,000.Target entity GITCPL reported a turnover of ₹19.28 lakhs for FY 2025-26, up from ₹8.14 lakhs in FY 2024-25.Strategic move to provide customized ERP, cloud-based software, and mobile applications to the Zota Group.The transaction was completed on June 22, 2026, at an arm's length basis with no promoter interest.GITCPL officially becomes a subsidiary of Zota Health Care Limited post-acquisition.
👀 கவனிக்க வேண்டியவை
While the acquisition is small in financial scale, it is a strategic move to strengthen internal digital capabilities; investors should watch for improvements in operational efficiency and software integration across the group.
Zota Health Care Invests ₹2 Crore in Subsidiary KMHP Ventures for Retail Expansion
Zota Health Care has subscribed to a rights issue of its wholly-owned subsidiary, KMHP Ventures Limited, acquiring 20,00,000 equity shares at ₹10 each. The total investment of ₹2 crore is a strategic move to fund the rollout of the 'Ugo Generic' retail brand, which will operate in both B2B and B2C pharmaceutical segments. KMHP is a newly incorporated entity (January 2026) that aims to establish a PAN India presence through owned stores and by onboarding approximately 12.5 lakh retail pharmacies. Post-acquisition, KMHP continues to be a 100% wholly-owned subsidiary of Zota Health Care.
முக்கிய அம்சங்கள்
Acquired 20,00,000 equity shares of KMHP Ventures Limited at a price of ₹10 per share.Total cash consideration for the acquisition amounts to ₹2,00,00,000 (₹2 Crore).Investment intended to fund the 'Ugo Generic' brand rollout and meet working capital requirements.Strategic goal to onboard ~12.5 lakh retail pharmacies under the Ugo Generic network across India.KMHP Ventures remains a Wholly Owned Subsidiary (WOS) following this capital infusion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution and scaling of the 'Ugo Generic' retail model, as the successful onboarding of 12.5 lakh pharmacies could significantly boost Zota's market reach and revenue.
Zota Health Care Invests ₹2 Crores in Subsidiary Curexis Ventures via Rights Issue
Zota Health Care has subscribed to a rights issue of its wholly-owned subsidiary, Curexis Ventures Private Limited, acquiring 10,00,000 equity shares. The total investment amounts to ₹2,00,00,000 (₹2 Crores) at a price of ₹20 per share, including a ₹10 premium. The capital infusion is intended to fund the expansion of the 'SKIA' retail pharmacy brand and support working capital requirements. Curexis is a nascent entity, reporting a turnover of only ₹1.18 Lakhs in FY 2025-26.
முக்கிய அம்சங்கள்
Acquired 10,00,000 equity shares of wholly-owned subsidiary Curexis Ventures Private Limited.Total cash consideration of ₹2,00,00,000 at an acquisition price of ₹20 per share.Investment aimed at strategic expansion of 'SKIA' brand retail pharmacy stores.Curexis remains a 100% wholly-owned subsidiary post-transaction.Target entity Curexis reported a turnover of ₹1.18 Lakhs for the financial year 2025-26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth and store-count trajectory of the 'SKIA' retail brand to see if this capital infusion translates into meaningful revenue contribution from the subsidiary.
Zota Health Care to Acquire 80% Stake in Globotask IT Consultancy for Rs 25 Lakhs
Zota Health Care Limited has entered into a Memorandum of Understanding (MOU) to acquire an 80% controlling stake in Globotask IT Consultancy Services Private Limited. The deal involves the acquisition of 8,000 equity shares for a total cash consideration of Rs 25,00,000. This strategic acquisition is intended to provide in-house IT solutions, including ERP software and mobile application development, for Zota and its subsidiaries. The company has also announced a trading window closure starting June 19, 2026, in relation to this development.
முக்கிய அம்சங்கள்
Acquisition of 80% majority stake in Globotask IT Consultancy Services Private Limited.Total aggregate consideration for the acquisition is Rs 25,00,000 (Twenty-Five Lakhs).Target company specializes in cloud-based software, Android/iOS apps, and customized ERP solutions.The transaction is not a related party transaction and involves no interest from promoters.Trading window closed from June 19, 2026, until 48 hours after the announcement.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of these IT services, which could lead to improved operational efficiency and cost savings in the long term. The small deal size suggests limited immediate financial impact but indicates a strategic focus on digital transformation.
Zota Health Care FY26 Revenue Jumps 84% to ₹538.6 Cr; EBITDA Turns Positive at ₹26 Cr
Zota Health Care reported a robust 83.86% YoY revenue growth for FY26, reaching ₹53,865 lakhs, primarily driven by the Davaindia retail segment. The company achieved a significant turnaround, posting a positive EBITDA of ₹2,597 lakhs for FY26 compared to an operating loss in FY25. The retail network expanded by 997 stores during the year to a total of 2,579, with same-store growth (SSG) remaining strong at 35-60%. Management has set a target of 5,000+ stores by FY29 and plans to add 500-700 stores in FY27 while focusing on profitability.
முக்கிய அம்சங்கள்
Consolidated revenue increased 83.86% YoY to ₹53,865 lakhs, with Davaindia sales nearly doubling to ₹41,741 lakhs.EBITDA turned positive at ₹2,597 lakhs (4.82% margin) for FY26, with Q4 margins reaching 7.3%.Added 997 stores in a single year, the highest in the Indian pharma retail segment, totaling 2,579 stores.Gross margin expanded by 714 basis points to 60.28%, aided by backward integration and scale benefits.Successfully raised ₹350 crore through a QIP to strengthen the balance sheet and fund the expansion to 5,000+ stores by FY29.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition from aggressive expansion to store-level profitability in the coming quarters. The strong same-store growth and positive EBITDA trend make it a key player to watch in the affordable healthcare retail space.
Zota Health Care FY26 Revenue Hits ₹538.66 Cr; Davaindia Network Reaches 2,579 Stores
Zota Health Care reported a consolidated revenue of ₹538.66 crore for FY26, driven largely by its Davaindia retail generic pharmacy chain which now contributes 73% of total revenue. The company significantly expanded its footprint to 2,579 stores, with a strategic shift toward Company-Owned Company-Operated (COCO) models which now number 1,656. Financial performance showed a strong Gross Profit of ₹324.69 crore, though EBITDA stood at ₹25.98 crore, reflecting high operational investments. Key corporate actions during the year included a successful ₹350 crore QIP and increasing the stake in Everyday Herbal Group to 87.78%.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations reached ₹53,865.75 lakhs (₹538.66 Cr) for FY26.Davaindia retail network expanded to 2,579 stores, achieving a Gross Merchandise Value (GMV) of ₹457.06 Cr.Successfully completed a ₹350 Cr QIP to fund expansion and acquired a 100% stake in Curexis.Gross Profit margin remains high at approximately 60%, although EBITDA margin is lower at 4.8% due to aggressive COCO store rollouts.Increased ownership in Everyday Herbal Group to 87.78% to strengthen backward integration and OTC product portfolio.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to scale EBITDA margins as the newly opened COCO stores mature and operational leverage kicks in. The successful capital raise and aggressive store expansion position Zota as a dominant player in the private-label generic pharmacy space.
Zota Health Care Reports 84% Revenue Growth in FY26; EBITDA Turns Positive at ₹26 Cr
Zota Health Care reported a massive 83.86% YoY increase in consolidated revenue to ₹53,865.75 lakhs for FY26. The company achieved a significant turnaround in profitability, with EBITDA reaching ₹2,597.73 lakhs compared to a loss in the previous fiscal year. The Davaindia retail network expanded aggressively, adding 997 stores to reach a total of 2,579 nationwide. Gross margins also saw a healthy expansion of 714 basis points to 60.28%, driven by scale and backward integration.
முக்கிய அம்சங்கள்
Consolidated Revenue grew 83.86% YoY to ₹53,865.75 lakhs in FY26.EBITDA turned positive at ₹2,597.73 lakhs in FY26 versus a loss of ₹366.51 lakhs in FY25.Davaindia network expanded to 2,579 stores, with 997 new stores added in a single year.Gross Margin expanded by 714 bps to 60.28% due to improved scale and integration.Company invested ₹19.47 crore to increase stake in Everyday Herbal Beauty Care to 87.78%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins while scaling towards its target of 5,000 stores by FY29. The successful turnaround in EBITDA and strong revenue momentum make it a key player to watch in the affordable healthcare retail segment.
Zota Health Care Promoter Directors Cap Cumulative Annual Remuneration at Rs 12 Crore
Promoter directors of Zota Health Care have voluntarily fixed an upper cap on their cumulative annual remuneration at Rs 12.00 crores. This aggregate limit applies to five key promoter directors, including the Chairman and Managing Director, and covers all perquisites and allowances. The move is aimed at enhancing corporate governance and ensuring more capital is available for the company's growth. This voluntary cap is scheduled to remain in effect until the end of the financial year 2030.
முக்கிய அம்சங்கள்
Cumulative annual remuneration for five promoter directors capped at an aggregate of Rs 12.00 crores.The voluntary cap is valid for a long-term period ending in the financial year 2030.Involves the Non-executive Chairman, Managing Director, and three Whole-time Directors.Objective is to moderate managerial pay and improve capital allocation for business expansion.
👀 கவனிக்க வேண்டியவை
This voluntary cap is a positive sign of promoter discipline and alignment with shareholder interests. Investors should view this as a commitment to fiscal prudence and better corporate governance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
